Menu

Blog

Nov 9, 2021

Regeneron’s COVID antibody drug shows protection for up to 8 months

Posted by in categories: biotech/medical, law enforcement

The antibody therapy, REGEN-COV, is currently authorized in the United States to treat people with mild-to-moderate COVID-19 and for prevention of infection in those exposed to infected individuals, and others at high risk of exposure in settings such as nursing homes or prisons. [USN: L4N2P640O]

The extended authorization could help boost sales of Regeneron’s antibody cocktail, in the face of competition from oral COVID-19 pills such as those being developed by Pfizer Inc (PFE.N) and Merck & Co (MRK.N).


Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in a late-stage trial, in the two to eight months period following the drug’s administration.

Comments are closed.